Economic burden of patients with leading cancers in China: a cost-of-illness study
China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patie...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
27 September 2024
|
| In: |
BMC health services research
Year: 2024, Jahrgang: 24, Pages: 1-13 |
| ISSN: | 1472-6963 |
| DOI: | 10.1186/s12913-024-11514-x |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/s12913-024-11514-x Verlag, kostenfrei, Volltext: https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-024-11514-x 
|
| Verfasserangaben: | Ziting Wu, Yiwen Yu, Feng Xie, Qiushi Chen, Zhong Cao, Simiao Chen and Gordon G. Liu |
| Zusammenfassung: | China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China. |
|---|---|
| Beschreibung: | Gesehen am 17.06.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1472-6963 |
| DOI: | 10.1186/s12913-024-11514-x |